A Switch in Dehydrogenase to Reductase Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 upon Differentiation of Human Omental Adipose Stromal Cells
Author(s) -
Iwona Bujalska,
Elizabeth A. Walker,
Martin Hewison,
Paul M. Stewart
Publication year - 2002
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jcem.87.3.8301
Subject(s) - 11β hydroxysteroid dehydrogenase type 1 , adipose tissue , endocrinology , medicine , adipocyte , stromal cell , cortisone , dehydrogenase , adipogenesis , lipoprotein lipase , insulin , biology , chemistry , enzyme , biochemistry
As exemplified in patients with Cushing’s syndrome, glucocorticoids play an important role in regulating adipose tissue distribution and function, but circulating cortisol concentrations are normal in most patients with obesity. However, human omental adipose stromal cells (ASCs) can generate glucocorticoid locally through the expression of the enzyme 11β-hydroxysteroid dehydrogenase (11β-HSD) type 1 (11β-HSD1), which, in intact cells, has been considered to be an oxoreductase, converting inactive cortisone (E) to cortisol (F). Locally produced F can induce ASC differentiation, but the relationship between 11β-HSD1 expression and adipocyte differentiation is unknown. Primary cultures of paired omental (om) and sc ASC and adipocytes were prepared from 17 patients undergoing elective abdominal surgery and cultured for up to 14 d. Expression and activity of 11β-HSD isozymes were analyzed together with early (lipoprotein lipase) and terminal (glycerol 3 phosphate dehydrogenase) markers of adipocyte differentiation. On d 1 of culture, 11β-HSD1 activity in intact om ASCs exceeded oxoreductase activity in every patient (78.9 ± 24.9 vs. 15.8 ± 3.7 [mean ± se] pmol/mg per hour, P < 0.001), and in sc ASCs, relative activities were similar (40.6 ± 12.2 vs. 36.9 ± 8.8). Conversely, in freshly isolated om adipocytes, reductase activity exceeded dehydrogenase activity (23.6 ± 1.5 vs. 6.2 ± 0.8 pmol/mg per hour, P < 0.01). Following 14 d of culture in serum-free conditions with addition of 10 nm insulin (Ctr) or insulin with 100 nm F (+F), lipoprotein lipase/18S RNA levels increased in both the Ctr- and +F-treated ASCs, but glycerol 3 phosphate dehydrogenase increased only in the +F cultures. In both cases, however, 11β-HSD1 oxoreductase activity exceeded dehydrogenase activity (Ctr: 53.3 ± 9.0 vs. 32.4 ± 10.5, P < 0.05; +F: 65.6 ± 15.6 vs. 37.1 ± 11.5 pmol/mg per hour, P < 0.05), despite no significant changes in 11β-HSD1 mRNA levels. In sc ASCs, dehydrogenase activity was similar to reductase activity in both Ctr- and +F-treated cells. Type 2 11β-HSD expression was undetectable in each case. These data show that in intact, undifferentiated om ASCs, 11β-HSD1 acts primarily as a dehydrogenase, but in mature adipocytes oxoreductase activity predominates. Because glucocorticoids inhibit cell proliferation, we postulate that 11β-HSD1 activity in uncommitted ASCs may facilitate proliferation rather than differentiation. Once early differentiation is initiated, a “switch” to 11β-HSD1 oxoreductase activity generates F, thus promoting adipogenesis. Site-specific regulation of the set-point of 11β-HSD1 activity may be an important mechanism underpinning visceral obesity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom